In this video, Walter Scott client investment manager Murdo MacLean considers Novo Nordisk’s recent challenges and touches on what the future could look like for the Danish pharma giant.
Key points:
- Unprecedented demand for GLP-1 weight-loss drug has strained Novo Nordisk and competitor Eli Lilly’s early supply.
- Rival online firms have offered cheaper generic versions of these drugs by exploiting US Food and Drug Administration (FDA) loopholes.
- Both Novo and Lilly have expanded manufacturing capacity and pivoted to direct-to-consumer to control pricing and margins.
- New Novo CEO brings sharper execution, clearer pipeline communication, and market-focused strategy.
- Novo is planning on launching the first oral GLP-1 in early 2026.
